Sistema de Información Esencial en Terapéutica y Salud


Última actualización: 18/9/2017
SIETES contiene 92005 citas

 1 a 20 de 24 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Trifirò G, de Ridder M, Sultana J, Oteri A, Rijnbeek P, Pecchioli S, Mazzaglia G, Bezemer I, Garbe E, Schink T, Poluzzi E, Froslev T, Molokhia M, Diemberger I, Sturkenboom M. Use of azithromycin and risk of ventricular arrhytmia. CMAJ 2017;189:E560-8. [Ref.ID 101536]
2.Enlace a cita original Cita con resumen
Oteri A, Mazzaglia G, Pecchioli S, Molokhia M, Ulrichsen SP, Pedersen L, Poluzzi E, De Ponti F, Garbe E, Schink T, Trifirò G. Prescribing pattern of antipsychotic drugs during the years 1996–2010: a population-based database study in Europe with a focus on torsadogenic drugs. Br J Clin Pharmacol 2016;82:487-97. [Ref.ID 100690]
3.Enlace a cita original
Naldi I, Piccinni C, Mostacci B, Renzini J, Accetta G, Bisulli F, Tappatà M, Piazza A, Pagano P, Bianchi S, D'Alessandro R, Tinuper P, Poluzzi E, ESPEA (Emilia-Romagna Study on Pregnancy and Exposure to Antiepileptic drugs) Group. Prescription patterns of antiepileptic drugs in young women: development of a tool to distinguish between epilepsy and psychiatric disorders. Pharmacoepidemiol Drug Saf 2016;25:763-9. [Ref.ID 100477]
4. Cita con resumen
Poluzzi E, Piccinni C, Sangiorgi E, Clo M, Tarricone I, Menchetti M, De Ponti F. Trend in SSRI-SNRI antidepressants prescription over a 6-year period and predictors of poor adherence. Eur J Clin Pharmacol 2013;69:2095-101. [Ref.ID 96640]
5. Cita con resumen
Poluzzi E, Raschi E, Koci A, Moretti U, Spina E, Behr ER, Sturkenboom M, De Ponti F. Antipsychotics and torsadogenic risk: signals emerging from the US FDA Adverse Event Reporting System database. Drug Saf 2013;36:467-79. [Ref.ID 95666]
6. Cita con resumen
Motola D, Piccinni C, Biagi C, Raschi E, Marra A, Marchesini G, Poluzzi E. Cardiovascular, ocular and bone adverse reactions associated with thiazolidinediones: a disproportionatlity analysis of the US FDA adverse event reporting system database. Drug Saf 2012;35:315-23. [Ref.ID 92760]
7.Enlace a cita original Cita con resumen
Piccini C, Motola D, Marchesini G, Poluzzi E. Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting. Diabetes Care 2011;34:1. [Ref.ID 90426]
8.Enlace a cita original
Chiabrando G, Bianchi S, Poluzzi E, Montanaro N, Scanavacca P. Profile of atypical-antipsychotics use in patients affected by dementia in the University Hospital of Ferrara. Eur J Clin Pharmacol 2010;66:661-9. [Ref.ID 88814]
Poluzzi E, Raschi E, Motola D, Moretti U, De Ponti F. Antimicrobials and the risk of torsades de pointes: the contribution from data mining of the US FDA adverse event reporting system. Drug Saf 2010;33:303-14. [Ref.ID 88227]
10.Enlace a cita original
Piccinni C, Sacripanti C, Poluzzi E, Motola D, Magro L, Moretti U, Conforti A, Montanaro N. Stronger association of drug-induced progressive multifocal leukoencephalopathy (PML) with biological immunomodulating agents. Eur J Clin Pharmacol 2010;66:199-206. [Ref.ID 87678]
11.Enlace a cita original
Poluzzi E, Raschi E, Moretti U, De Ponti F. Drug-induced torsades de pointes: data mining of the public version of the FDA Adverse Event Reporting System (AERS). Pharmacoepidemiol Drug Saf 2009;18:512-8. [Ref.ID 86355]
12. Cita con resumen
Raschi E, Poluzzi E, Zuliani C, Muller A, Goossens H, De Ponti F. Exposure to antibacterial agents with QT liability in 14 European countries: trends over and 8-year period. Br J Clin Pharmacol 2009;67:88-98. [Ref.ID 84983]
13. Cita con resumen
Poluzzi E, Strahinja P, Lanzoni M, Vargiu A, Silvani MC, Motola D, Gaddi A, Vaccheri A, Montanaro N. Adherence to statin therapy and patients' cardiovascular risk: a pharmacoepidemiological study in Italy. Eur J Clin Pharmacol 2008;64:425-32. [Ref.ID 82633]
14. Cita con resumen
Poluzzi E, Strahinja P, Vaccheri A, Vargiu A, Silvani MC, Motola D, Marchesini G, De Ponti F, Montanaro N. Adherence to chronic cardiovascular therapies: persistence over the years and dose coverage. Br J Clin Pharmacol 2007;63:346-55. [Ref.ID 79456]
15. Cita con resumen
Motola D, De Ponti F, Poluzzi E, Martini N, Rossi P, Silvani MC, Vaccheri A, Montanaro N. An update on the first decade of the European centralized procedure: how many innovative drugs?. Br J Clin Pharmacol 2006;62:610-6. [Ref.ID 78427]
Poluzzi E, Strahinja P, Vargiu A, Chiabrando G, Silvani MC, Motola D, Cellini GS, Vaccheri A, De Ponti F, Montanaro N. nitital treatment of hypertension and adherence to therapy in general practice in Italy. Eur J Clin Pharmacol 2005;61:603-9. [Ref.ID 75026]
Motola D, Vaccheri A, Silvani MC, Poluzzi E, Bottoni A, De Ponti F, Montanaro N. Pattern of NSAID use in the Italian general population: a questionnaire-based survey. Eur J Clin Pharmacol 2004;60:731-8. [Ref.ID 72310]
18. Cita con resumen
Poluzzi E, Motola D, Silvani C, De Ponti F, Vaccheri A, Montanaro N. Prescriptions of antidepressants in primary care in Italy: pattern of use after admission of selective serotonin reuptake inhibitors for reimbursement. Eur J Clin Pharmacol 2004;59:825-31. [Ref.ID 68901]
19. Cita con resumen
De Ponti F, Poluzzi E, Vaccheri A, Bergman U, Bjerrum L, Ferguson J, Frenz KJ, McManus P, Schubert I, Selke G, Terzis-Vaslamatzis G, Montanaro N. Non-antiarrhythmic drugs prolonging the QT interval: considerable use in seven countries. Br J Clin Pharmacol 2002;54:171-7. [Ref.ID 63048]
De Ponti F, Poluzzi E, Cavalli A, Recanatini M, Montanaro N. Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsade de pointes: an overview. Drug Saf 2002;25:263-86. [Ref.ID 61881]
Seleccionar todas
 1 a 20 de 24 siguiente >>